Jianhui Ma
Peking Union Medical College
32 Papers
39 Citations
Jianhui Ma is an academic researcher from Peking Union Medical College. The author has contributed to research in topics: Renal cell carcinoma & Medicine. The author has an hindex of 8, co-authored 25 publications.
Chat about Author
Papers
Anlotinib Versus Sunitinib as First-Line Treatment for Metastatic Renal Cell Carcinoma: A Randomized Phase II Clinical Trial
Ai Ping Zhou,Yuxian Bai,Yan Song,Hong Luo,Xiu Bao Ren,Xiuwen Wang,Benkang Shi,Cheng Fu,Ying Cheng,Ji-Yan Liu,Shukui Qin,Jun Li,Hanzhong Li,Xianzhong Bai,Dingwei Ye,Jinwan Wang,Jianhui Ma +16 more
TL;DR: The clinical efficacy of anlotinib was similar to that of sunitinib as the first-line treatment for mRCC, but with a more favorable safety profile.
94
Chinese guidelines on the management of renal cell carcinoma (2015 edition)
Jun Guo,Jianhui Ma,Yan Sun,Shukui Qin,Dingwei Ye,Fangjian Zhou,Zhisong He,Xinan Sheng,Feng Bi,Dengfeng Cao,Yingxia Chen,Yiran Huang,Houjie Liang,Jun Liang,Jiwei Liu,Wenchao Liu,Yueyin Pan,Yongqian Shu,Xin Song,Weibo Wang,Xiuwen Wang,Xiaoan Wu,Xiaodong Xie,Xin Yao,Shiying Yu,Yanqiao Zhang,Aiping Zhou +26 more
TL;DR: The renal cancer referred in these guidelines is the renal cell carcinoma (RCC) and does not include various tumors originated from renal interstitium and renal pelvis/urothelial system.
Long-term survival and prognostic factors for locally advanced renal cell carcinoma with renal vein tumor thrombus
Chuanzhen Cao,Chuanzhen Cao,Xingang Bi,Jing Liang,Lin Li,Huijuan Zhang,Zhendong Xiao,Zejun Xiao,Jun Tian,Dong Wang,Kaopeng Guan,Changling Li,Jianhui Ma,Shan Zheng,Jianzhong Shou +14 more
TL;DR: After radical surgery, RCC patients with RVTT had a relatively fair prognosis except for patients with friable thrombus, PNS, higher modified Fuhrman grade and perirenal fat invasion.
•Journal Article
Famitinib in metastatic renal cell carcinoma: a single center study.
TL;DR: Famitinib has significant anti‐tumor activity in mRCC and the common adverse reactions are generally manageable.
22
Chinese guidelines on the management of renal cell carcinoma (2015 edition)
Jun Guo,Jianhui Ma,Yan Sun,Shukui Qin,Dingwei Ye,Fangjian Zhou,Zhisong He,Xinan Sheng,F. Bi,Dengfeng Cao,Yingxia Chen,Yi-Ran Huang,Houjie Liang,Jiwei Liu,Wenchao Liu,Yueyin Pan,Yongqian Shu,Xin Song,Weibo Wang,Xiuwen Wang,Xiaoan Wu,Xiaodong Xie,Xin Yao,Shiying Yu,Yanqiao Zhang,Aiping Zhou +25 more
TL;DR: The renal cancer referred in these guidelines is the renal cell carcinoma (RCC) and does not include various tumors originated from renal interstitium and renal pelvis/urothelial system.